文献速递头颈与中枢神经肿瘤

靶向小胶质细胞代谢重编程与免疫检查点阻断治疗胶质母细胞瘤的协同作用

Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma.
PubMed 文献 · Cancer Discov · 2023-01-01

该研究通过单细胞测序发现胶质母细胞瘤免疫微环境中小胶质细胞处于严重氧化应激状态,诱导NR4A2依赖性转录活性;遗传靶向Nr4a2或药物抑制NR4A2/SQLE可重塑小胶质细胞可塑性、减少替代激活小胶质细胞、增强CD8+ T细胞抗原呈递能力,并在体内增强免疫检查点阻断疗效。

要点

  • 胶质母细胞瘤免疫微环境中小胶质细胞处于严重氧化应激,诱导NR4A2依赖性转录活性。
  • 遗传靶向Nr4a2减少替代激活小胶质细胞并增强CD8+ T细胞抗原呈递能力。
  • 药物抑制NR4A2或靶向SQLE可增强免疫检查点阻断的体内疗效。

核心结论

  • 氧化应激通过小胶质细胞中NR4A2-SQLE活性促进肿瘤生长,为脑肿瘤免疫治疗提供新范式。

研究设计与样本

  • 研究对胶质母细胞瘤免疫微环境进行单细胞测序,并使用Nr4a2+/-及Nr4a2fl/flCx3cr1Cre遗传靶向小鼠模型。

主要发现

  • 单细胞测序显示胶质母细胞瘤免疫微环境中小胶质细胞处于严重氧化应激,诱导NR4A2依赖性转录活性。
  • Nr4a2+/-或CX3CR1+髓系细胞特异性Nr4a2靶向在体内减少替代激活小胶质细胞并增强CD8+ T细胞抗原呈递能力。
  • 小胶质细胞中NR4A2激活角鲨烯单加氧酶(SQLE)导致胆固醇稳态失调。
  • 药物抑制NR4A2减轻促肿瘤免疫微环境,靶向NR4A2或SQLE增强免疫检查点阻断的体内疗效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Glioblastoma (GBM) constitutes the most lethal primary brain tumor for which immunotherapy has provided limited benefit. The unique brain immune landscape is reflected in a complex tumor immune microenvironment (TIME) in GBM. Here, single-cell sequencing of the GBM TIME revealed that microglia were under severe oxidative stress, which induced nuclear receptor subfamily 4 group A member 2 (NR4A2)-dependent transcriptional activity in microglia. Heterozygous Nr4a2 (Nr4a2+/-) or CX3CR1+ myeloid cell-specific Nr4a2 (Nr4a2fl/flCx3cr1Cre) genetic targeting reshaped microglia plasticity in vivo by reducing alternatively activated microglia and enhancing antigen presentation capacity for CD8+ T cells in GBM. In microglia, NR4A2 activated squalene monooxygenase (SQLE) to dysregulate cholesterol homeostasis. Pharmacologic NR4A2 inhibition attenuated the protumorigenic TIME, and targeting the NR4A2 or SQLE enhanced the therapeutic efficacy of immune-checkpoint blockade in vivo. Collectively, oxidative stress promotes tumor growth through NR4A2-SQLE activity in microglia, informing novel immune therapy paradigms in brain cancer. SIGNIFICANCE: Metabolic reprogramming of microglia in GBM informs synergistic vulnerabilities for immune-checkpoint blockade therapy in this immunologically cold brain tumor. This article is highlighted in the In This Issue feature, p. 799.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Ye Z, Ai X, Yang K, et al. Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma. Cancer Discov. 2023. PMID: 36649564. doi:10.1158/2159-8290.CD-22-0455

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。